4,508 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC acquired a new position in Annovis Bio, Inc. (NYSE:ANVS) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,508 shares of the company’s stock, valued at approximately $386,000.

A number of other large investors have also modified their holdings of ANVS. Geode Capital Management LLC bought a new stake in Annovis Bio in the first quarter worth $769,000. Northern Trust Corp acquired a new position in Annovis Bio during the 1st quarter worth $207,000. Renaissance Technologies LLC acquired a new position in Annovis Bio during the 1st quarter worth $555,000. Citadel Advisors LLC acquired a new position in Annovis Bio during the 1st quarter worth $250,000. Finally, Virtu Financial LLC acquired a new position in Annovis Bio during the 1st quarter worth $222,000. Hedge funds and other institutional investors own 15.79% of the company’s stock.

Separately, Maxim Group began coverage on shares of Annovis Bio in a research report on Friday, October 8th. They set a “buy” rating and a $70.00 target price for the company.

Annovis Bio stock opened at $25.86 on Thursday. The firm has a market cap of $209.49 million, a price-to-earnings ratio of -18.34 and a beta of 1.86. Annovis Bio, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $132.00. The stock’s fifty day moving average price is $30.75.

Annovis Bio (NYSE:ANVS) last released its earnings results on Tuesday, November 2nd. The company reported ($0.35) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.09.

In related news, CEO Maria-Luisa Maccecchini acquired 18,000 shares of the business’s stock in a transaction dated Monday, October 11th. The stock was acquired at an average price of $27.61 per share, with a total value of $496,980.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 42.60% of the stock is currently owned by corporate insiders.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders.

Featured Article: Oversold

Want to see what other hedge funds are holding ANVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annovis Bio, Inc. (NYSE:ANVS).

Institutional Ownership by Quarter for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.